drugset / Trial / NCT06862284
Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to explore the efficacy and safety of upadacitinib and clarify the influence on immune function in the treatment of primary Sjögren's Syndrome.
Timeline
- Start
- 2025-03-10
- Primary completion
- 2026-12-30
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Subject | Upadacitinib | Small molecule | 15 mg | Oral |